The “brain‑eating” virus most of us carry—and why doctors are rethinking its risks

Background

If you’ve never heard of JC virus (short for John Cunningham virus), you’re not alone—and yet there’s a good chance you already carry it. By middle age, 50–80% of people worldwide have antibodies that show prior exposure. For nearly everyone, JC virus is a quiet passenger. It sets up shop in places like the kidneys, bone marrow, and tonsils, barely causing a ripple.

The menace only becomes apparent when the virus breaches the brain and infects oligodendrocytes, the cells that wrap nerve fibers in myelin. When these cells die, myelin unravels, neural signals short‑circuit, and a rare, often fatal disease—progressive multifocal leukoencephalopathy (PML)—can take hold. Patients can develop weakness, clumsiness, vision loss, speech problems, personality or cognitive changes, and, without swift intervention, rapid neurologic decline.

For decades, doctors taught a simple rule: PML is essentially a consequence of extreme immune collapse. That view was shaped by the AIDS crisis, in which advanced HIV infection left patients susceptible, and by cases among organ transplant recipients on heavy immunosuppression. But medicine has changed. So have the ways we modulate immunity. And accumulating evidence now shows the old rule is too narrow.

What happened

Over the last several years, clinicians have documented more cases of PML in contexts that don’t fit the historic mold of “profound” immune suppression. That doesn’t mean the disease is common—it remains rare. It does mean the line between “safe” and “at risk” is blurrier than once believed.

What’s shifting the picture?

1. A wider use of targeted immune therapies

• Biologic drugs that reshape immune surveillance are now routine for multiple sclerosis (MS), lymphomas, leukemias, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and more. Therapies that touch B cells (e.g., anti‑CD20 antibodies), block immune cell trafficking (e.g., integrin inhibitors), or restrain lymphocyte counts (e.g., sphingosine‑1‑phosphate modulators) all change how the body patrols for latent viruses in tissues—including the brain.
• The best‑known example is natalizumab, an MS therapy that dramatically reduces relapses but, in certain scenarios, raises PML risk. Over time, clinicians noticed similar, if typically lower, risks with other agents including rituximab and ocrelizumab (B‑cell depletion), dimethyl fumarate (lymphopenia), and older agents like efalizumab (withdrawn). The implication: you don’t need to “turn the immune system off” to change the JC virus equation; nudging specific arms or checkpoints can be enough.

2. Subtle and transient immune dips still matter

• Case series have described PML in people without classic risk factors: modest, chronic lymphopenia; age‑related immune senescence; hematologic cancers in remission; malnutrition; and rare idiopathic CD4 lymphocytopenia. A small number of “apparently immunocompetent” cases have been reported, though clinicians often discover an underappreciated vulnerability on closer work‑up.
• The theme is consistent: the balance between JC virus and host immunity can tip without the headline‑grabbing immune collapse seen in untreated AIDS or deep post‑transplant suppression.

3. Better detection reveals a broader spectrum

• MRI has grown more sensitive in spotting the telltale patterns of demyelination before catastrophic symptoms. Cerebrospinal fluid (CSF) PCR tests for JC virus DNA are faster and more widely available. Together, these tools are catching cases earlier—and in settings where clinicians previously might not have suspected PML at all.

4. JC virus isn’t a bystander in the brain

• For years, the dogma placed JC virus in the kidneys and bone marrow, with the brain involved only during advanced disease. Autopsy and molecular studies now suggest the virus (or its genetic traces) can be found in brain tissue far more often than anyone expected, likely reflecting low‑level, immune‑controlled presence. Most of the time, this amounts to “surveillance under control.” But it indicates the CNS is part of the virus’s ecological niche, not just a late‑stage accident.

What’s the practical upshot? Physicians are recalibrating how they counsel patients about JC virus when starting or sequencing immune‑modifying therapies, and how quickly they investigate puzzling neurologic symptoms. Risk is still small for the vast majority of people on these medicines—but it’s not negligible, and it’s no longer confined to the classic categories of extreme immunodeficiency.

How JC virus causes damage

• Transmission and latency: JC virus likely spreads through saliva or urine, often in childhood. After a silent primary infection, it establishes latency in the kidneys and immune cells. Most people never experience illness.
• CNS entry: Under permissive conditions (immunologic changes, inflammation altering the blood–brain barrier, or cellular “reprogramming” of the virus), JC virus can reach the brain. There, it infects and lyses oligodendrocytes, eroding myelin in scattered patches—hence “multifocal” leukoencephalopathy.
• Symptoms: Depending on where lesions occur, patients may notice progressive weakness, numbness, ataxia, word‑finding difficulty, vision loss, or cognitive/behavioral changes. Seizures are less common but possible. Fever and headache are not reliable clues.
• Diagnosis: MRI showing non‑enhancing white‑matter lesions that don’t respect vascular territories raises suspicion. CSF PCR for JC virus DNA provides confirmation. When CSF is negative yet suspicion remains, a brain biopsy can clinch the diagnosis.
• Prognosis: Without immune recovery, mortality is high and survivors often have lasting deficits. With early detection and reversal of the precipitating immune problem, outcomes improve, though many patients have some residual disability.

Who is at risk now?

Risk remains very low for most people, and the vast majority of JC‑virus‑positive individuals will never develop PML. Nonetheless, patterns have changed enough to matter in day‑to‑day care:

• Profound immunosuppression (classic): advanced, untreated HIV; post‑transplant regimens; potent chemotherapy.
• Targeted immunotherapies (modern, heterogeneous risk):
  • Anti‑integrin agents (e.g., natalizumab for MS and Crohn’s disease).
  • B‑cell depleters (e.g., rituximab, ocrelizumab; also used in hematologic malignancies and autoimmune disease).
  • S1P modulators (e.g., fingolimod) and drugs that induce lymphopenia (e.g., dimethyl fumarate) when lymphocyte counts drop too low for too long.
  • Older or withdrawn agents with known risk (e.g., efalizumab).
• Subtle or chronic immune vulnerability: older age, low lymphocyte counts from various causes, certain hematologic conditions, and rare idiopathic immune defects.

Importantly, being JC‑virus–seropositive alone is not a diagnosis or a sentence. It is context: a common background fact that informs how clinicians select and monitor therapies.

Managing risk without panic

If you take a medicine that modulates the immune system, your clinician is already thinking about JC virus, whether or not it’s top of mind for you. Some practical principles guide care:

• Baseline and periodic JC‑virus antibody testing in select scenarios: In MS care with natalizumab, for example, a quantitative “antibody index” helps stratify risk and tailor treatment duration or switching strategies.
• Keep an eye on lymphocyte counts: For drugs known to lower lymphocytes, routine blood work guides dosing, holds, or therapy changes before risk accumulates.
• Respond early to neurologic changes: New, unexplained neurologic symptoms—especially if they evolve over days to weeks—warrant prompt evaluation and MRI rather than a wait‑and‑see approach.
• If PML is suspected: The priority is to restore immune surveillance. That can mean rapidly withdrawing or reversing the implicated drug (e.g., plasma exchange for natalizumab), addressing underlying infections, or adjusting cancer regimens.
• Beware of IRIS: When immune function rebounds, the nervous system can become inflamed—a phenomenon called immune reconstitution inflammatory syndrome (IRIS). It can paradoxically worsen symptoms short‑term and sometimes requires corticosteroids to control swelling.
• Experimental or adjunctive options: Antivirals have not been reliably effective. Immune‑based approaches—such as PD‑1 checkpoint inhibitors in carefully selected cases, or JC‑virus–specific T‑cell therapies under study—show promise but are not cure‑alls. Expert centers tailor these decisions.

Why “not anymore” matters

The simple takeaway—“PML only happens with near‑total immune collapse”—was comforting but incomplete. Today’s reality is subtler:

• Immune systems are being reshaped in targeted ways for millions of people. That brings enormous benefits for cancer, autoimmune disease, and transplantation—and small but real risks for latent infections.
• JC virus lives on a spectrum from inert passenger to opportunistic pathogen. Small shifts in immune surveillance or cell trafficking can push it along that spectrum.
• Recognizing atypical risk profiles leads to faster diagnosis, better outcomes, and more informed consent when starting therapy.

None of this should dissuade patients from lifesaving or life‑improving medications. Instead, it refines the risk–benefit conversation and underscores the value of vigilance.

Key takeaways

• Most adults have been exposed to JC virus without ever getting sick.
• PML, the severe brain disease linked to JC virus, remains rare—but not restricted to people with extreme immune suppression.
• Modern immune‑modifying drugs, modest or chronic lymphopenia, and age‑related immune changes can create windows of vulnerability.
• Early imaging and CSF testing improve detection; the fastest path to better outcomes is recognizing symptoms early and restoring immune control.
• Your individual risk depends on your diagnosis, medications, blood counts, JC‑virus antibody status, and overall immune health. Discuss specifics with your clinician rather than generalities from the internet.

What to watch next

• Smarter risk stratification: Expect more precise tools—beyond a simple antibody index—that combine viral markers, lymphocyte phenotyping, and clinical context to forecast risk.
• Safer treatment sequencing: Neurology and oncology programs continue to refine how long patients stay on higher‑risk agents, when to rotate, and how to bridge therapies to minimize PML risk without losing disease control.
• Immune‑based therapies for PML: Clinical trials of virus‑specific T cells, therapeutic vaccines, and carefully selected checkpoint inhibitors will clarify who benefits and how to time these interventions.
• Better virology: Understanding where JC virus hides, how it mutates to infect brain cells, and how it traffics into the CNS could yield true antivirals—still a major unmet need.
• Real‑world registries: Large, international datasets tracking PML cases across specialties will continue to recalibrate how we define “high risk” and guide screening.

FAQ

Q: Should I be tested for JC virus?
A: Not routinely. Testing is helpful in specific contexts—most commonly for people considering or taking certain MS drugs—because results can guide therapy choices. Ask your clinician if it’s relevant for you.

Q: If I’m JC‑virus positive, will I get PML?
A: No. Most JC‑virus–positive people never get PML. Risk depends on many factors, especially the type and duration of immune‑modifying therapy and the state of your immune system.

Q: What symptoms should prompt urgent evaluation?
A: New, progressive neurologic deficits—weakness, clumsiness, speech or vision changes, cognitive shifts—developing over days to weeks deserve prompt medical attention, especially if you’re on immune‑modifying therapy.

Q: Is there a cure for PML?
A: There’s no antiviral cure. The cornerstone is restoring immune control by stopping or reversing the trigger and managing inflammation (including IRIS). Some experimental immune therapies can help select patients.

Q: Should I stop my medication because of PML risk?
A: Do not stop prescribed therapy without medical advice. For most people, the benefits of modern therapies far outweigh the small PML risk. Discuss your personal risk and monitoring plan with your clinician.

---

Source & original reading: https://arstechnica.com/health/2026/03/youre-likely-already-infected-with-a-brain-eating-virus-youve-never-heard-of/